Plasma S100A8/A9 Level Predicts Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Overview

Journal Sci Rep

Date 2025 Jan 20

PMID 39833332

Authors

Tadahiro Kuribayashi

Rie Kinoshita

Kiichiro Ninomiya

Go Makimoto

Toshio Kubo

Kammei Rai

Eiki Ichihara

Katsuyuki Hotta

Masahiro Tabata

Yoshinobu Maeda

Katsuyuki Kiura

Shinichi Toyooka

Masakiyo Sakaguchi

Kadoaki Ohashi

Affiliations

Soon will be listed here.

Abstract

Blood-based predictive markers for the efficacy of immune checkpoint inhibitors (ICIs) have not yet been established. We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital. The pre-treatment plasma levels of S100A8/A9 were analyzed. Eighty-one eligible patients were included (median age, 69 years). Sixty-two patients were men, 54 had adenocarcinoma, 74 had performance status (PS) 0-1, and 47 received ICIs as first-line treatment. The median time to treatment failure (TTF) for ICIs was 5.7 months, and the median overall survival (OS) was 19.6 months. The TTF and OS were worse in patients with high plasma S100A8/A9 levels (≥ 2.475 µg/mL) (median TTF: 4.3 vs. 8.5 months, p = 0.009; median OS: 15.4 vs. 38.0 months, p = 0.001). Multivariate analysis revealed that PS ≥ 2, liver metastasis, and high plasma S100A8/A9 levels were significantly associated with short TTF and OS. In conclusion, plasma S100A8/A9 level may have a limited effect on ICI therapy for NSCLC.

References

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

Shields M, Marin-Acevedo J, Pellini B . Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. Am Soc Clin Oncol Educ Book. 2021; 41:1-23. DOI: 10.1200/EDBK_321483. View

Taube J, Klein A, Brahmer J, Xu H, Pan X, Kim J . Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20(19):5064-74. PMC: 4185001. DOI: 10.1158/1078-0432.CCR-13-3271. View

Wagner N, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V . Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer. 2019; 7(1):343. PMC: 6896585. DOI: 10.1186/s40425-019-0828-1. View

Patel S, Kurzrock R . PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14(4):847-56. DOI: 10.1158/1535-7163.MCT-14-0983. View

Ghiringhelli F, Bibeau F, Greillier L, Fumet J, Ilie A, Monville F . Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer. EBioMedicine. 2023; 92:104633. PMC: 10232659. DOI: 10.1016/j.ebiom.2023.104633. View

Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A . Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Mol Cancer. 2020; 19(1):141. PMC: 7488475. DOI: 10.1186/s12943-020-01260-z. View

Han C, Meng G, Ding Z, Dong Z, Chen Z, Hong J . The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol. 2022; 13:827788. PMC: 8861087. DOI: 10.3389/fimmu.2022.827788. View

Hernandez C, Huebener P, Schwabe R . Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016; 35(46):5931-5941. PMC: 5119456. DOI: 10.1038/onc.2016.104. View

10.

Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M . Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(4):522-528. PMC: 5885200. DOI: 10.1001/jamaoncol.2017.5236. View

11.

Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J . S100A8/A9 in Inflammation. Front Immunol. 2018; 9:1298. PMC: 6004386. DOI: 10.3389/fimmu.2018.01298. View

12.

Guven D, Sahin T, Erul E, Rizzo A, Ricci A, Aksoy S . The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Mol Biosci. 2022; 9:1039121. PMC: 9756377. DOI: 10.3389/fmolb.2022.1039121. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Tomonobu N, Kinoshita R, Sakaguchi M . S100 Soil Sensor Receptors and Molecular Targeting Therapy Against Them in Cancer Metastasis. Transl Oncol. 2020; 13(4):100753. PMC: 7078545. DOI: 10.1016/j.tranon.2020.100753. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T . Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. J Thorac Oncol. 2021; 16(12):2078-2090. DOI: 10.1016/j.jtho.2021.07.027. View

17.

Sprenkeler E, Zandstra J, van Kleef N, Goetschalckx I, Verstegen B, Aarts C . S100A8/A9 Is a Marker for the Release of Neutrophil Extracellular Traps and Induces Neutrophil Activation. Cells. 2022; 11(2). PMC: 8773660. DOI: 10.3390/cells11020236. View

18.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

19.

Shabani F, Farasat A, Mahdavi M, Gheibi N . Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018; 67(10):801-812. DOI: 10.1007/s00011-018-1173-4. View

20.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View